Data From A Randomized And Controlled Trial Of LCarnitine Prescription For The Treatment For Non- Alcoholic Fatty Liver Disease
Notes for this study:
||Number at Grade 1. Placebo: before 22(55%), after 30 (75%). Carnitine: before 7 (17.5%), after 9 (22.5%). Grade 2. Placebo: before 17(42.5%), after 10 (25%). Carnitine: before 31(77.5%), after 22 (55%). Grade 3 Placebo: before 1(2.5)%, after none. Carnitine: before 2 (5%) , after none.
|Number of Subjects
80 participants with non-alcoholic fatty liver who were in a randomized, controlled trial for those with gastroenterological were selected and received 250 mg of L-carnitine every 12 hours for 24 weeks or were in the control group. Both groups were recommended to exercise and consume a low fat diet.
There was a comparable reduction in AST and a greater reduction in ALT for the carnitine group. Liver fat didn't improve more in the carnitine group, and the groups were considerably different at baseline.